Recipharm will be at BIO International Convention, June 13-16, taking place in San Diego, USA.
Visit our team at booth #1204 or schedule a meeting with us ahead of time via BIO’s 1:1 partnering system to learn more about how we serve companies developing small molecules, drug devices - and now biologics after strategically acquiring three CDMO companies to expand our specialized capabilities in advanced and emerging therapeutics and vaccines.
Recipharm completed a series of strategic acquisitions in April 2022, welcoming premier industry CDMO specialists Arranta Bio, Genibet, and Vibalogics to the greater-Recipharm family. These companies expand Recipharm’s specialized CDMO capabilities from preclinical-to-clinical and commercial approval for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
Established in 1995, Recipharm’s manufacturing, fill-finish, and delivery device services canvass a wide variety of drug dosage forms and modalities. The company’s advanced and emerging customers will now be able to leverage an existing global presence aided by a robust company wide supply network and established synergies across technical laboratory and manufacturing operations, quality, and regulatory. As Recipharm expands its offerings, customers will still find the same commitment to personalized service, customizable and scalable end-to-end manufacturing solutions for which Recipharm and the acquired companies are known.